کد مقاله کد نشریه سال انتشار مقاله انگلیسی ترجمه فارسی نسخه تمام متن
5643609 1586474 2017 5 صفحه PDF سفارش دهید دانلود کنید
عنوان انگلیسی مقاله ISI
Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice
ترجمه فارسی عنوان
ایمنی و کارایی استفاده طولانی مدت از اکسیباتی سدیم در درمان نارکولپسی با کاتاپلکسی در روانپزشکی بالینی
موضوعات مرتبط
علوم زیستی و بیوفناوری علم عصب شناسی عصب شناسی
چکیده انگلیسی


- Sodium oxybate improves alertness in refractory to treatment patients with narcolepsy with cataplexy.
- Sodium oxybate improves cataplexy in refractory to treatment patients with narcolepsy with cataplexy.
- 1/4 of the patients had to withdraw from the drug due to side effects.
- In half of the patients sodium oxybate led to reduction of other drug dosages and in 10% to discontinuation.

BackgroundSodium oxybate is licensed in Europe for the treatment of narcolepsy with cataplexy in adults. The aim of this study was to assess the efficacy and safety of sodium oxybate in clinical practice in patients with narcolepsy and cataplexy refractory to other treatments.Materials and methodsThis was a retrospective single centre study including patients with severe narcolepsy with cataplexy refractory to other treatments, who were initiated on sodium oxybate between 2009 and 2015. Patients were allowed to be on other stimulants or/and anti-cataplectic agents. Epworth sleepiness scale (ESS) and weekly cataplexy events were recorded. Side effects (SEs) were recorded at every follow-up visit.Results90 patients were prescribed sodium oxybate, with a total of 3116 patient-months of drug exposure. ESS and weekly cataplexy events were significantly reduced by sodium oxybate for all patients (ΔESS = 4.3 ± 4.4 and Δcataplexy = 21.8 ± 18.5 events/week; p < 0.0001, respectively). The required maintenance dose could not be predicted based upon gender, body mass index, or clinical factors. 60% of patients were able to reduce or come off other medications. Half of the patients experienced at least one SE, and 26.6% had to stop treatment due to limiting SEs. Nausea, mood swings and enuresis were the most commonly reported SEs. SEs that led to drug discontinuation, particularly psychosis, were associated with increasing age and were observed early after the initiation of the drug.ConclusionsSodium oxybate provides a good clinical efficacy and acceptable safety profile in routine clinical practice for the treatment of patients suffering from narcolepsy with cataplexy. A quarter of patients experience SEs requiring withdrawal of the drug with older patients being more vulnerable to the more serious SEs.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Sleep Medicine - Volume 35, July 2017, Pages 80-84
نویسندگان
, , , , , , , , , , , ,